X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Australia Sepsis Study To Aid In New Antibiotic Discovery

Content Team by Content Team
5th April 2023
in Drug Development, News
GE Healthcare Launches Viral Vector Based Gene Therapy Manufacturing

Researchers from the University of Queensland in Australia have led a national study pertaining to four major bacteria that cause sepsis, thereby providing new targets when it comes to developing antibiotics.

Professor Mark Schembri and Professor Mark Walker from the university’s Institute of Molecular Biosciences, along with the University of Melbourne’s Dr. Andre Mu and teams from 23 organisations across Australia, had set up experiments in order to mimic what takes place to bacteria as and when they enter the blood stream during the course of the infection.

It is well to be noted that sepsis is the root cause of 20% of the deaths across the world, in which people succumb to heart attacks, strokes, colon, breast, or prostate cancer. It is often characterised by infection-led organ failure, leaving survivors with cognitive, physical, and psychological side effects that can be seen for the rest of their lives.

Apparently, the researchers have been able to characterise RNA, bacterial genes, proteins, and metabolites from E. coli, Klebsiella pneumoniae, Group A Streptococcus, as well as Staphylococcus, and combined the data so as to get an absolute picture of how different species go on to respond when grown in human blood serum.

The research also brought together the biological sciences communities and Australian bacterial-pathogen research and generated loads of data, which happens to be publicly accessible. Due to this, researchers from across the world will be able to pry out this dataset so as to drive antibiotic exploration and development, which is very pivotal considering the fast rise in antibiotics seen worldwide.

Notably, the antibiotic-resistant sepsis pathogens framework initiative consortium is very well supported due to the funding received from the Australian Government’s National Collaboration research infrastructure strategy led Bioplatforms Australia.

Previous Post

COVID-19 Hospitalisation Dips Using Monoclonal Antibodies

Next Post

Seamlessness In Patient Engagement Through eConsent Trial

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
Next Post
TrakCel and WindMIL Therapeutics partner on cell therapy supply chain management and orchestration platform

Seamlessness In Patient Engagement Through eConsent Trial

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In